In contrast, memory B-cells (CD19+IgM−/+CD27++), plasmablasts (CD19+IgM−/+CD138+CD27+), memory-plasmablasts (CD19+IgM−CD138+CD27++) and circulating marginal zone (CD19+CD27+CD23−) B-cells were significantly increased at diagnosis compared to post-treatment, suggesting their potential utility as TB-treatment response biomarkers (129). The gene discussed is CD19; the disease is tuberculosis.